Interventions in Minimal Residual Disease Lead to Long-Term Melanoma Control
Source: Dermatology Times, April 2023
Cutaneous melanoma responds to targeted therapies (TT) and immune checkpoint inhibitors (ICI) in 3 phases, according to a recent review.
In the review, authors also found that TT and ICI can affect both melanoma cells and the tumor immune microenvironment, particularly in the middle of the 3 phases. These phases are known as early response, minimal residual disease (MRD), and disease progression. More specifically, the review assessed the role of TT and ICI in the MRD phase.
Historically, the developments and implementations of TT and ICI have improved patient outcomes in metastatic melanoma. However, review authors said some questions of TT and ICI sequencing remain unresolved, stating that the goal of their review was to uncover more of the biology of the 3 phases, as well as determine a correlation and response between TT, ICI, and MRD.